Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 262 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

NCT00640224
Conditions
Polycystic Ovary Syndrome
Interventions
rosiglitazone, drospirenone/ethinyl estradiol
Drug
Lead sponsor
Silva Arslanian
Other
Eligibility
10 Years to 20 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934
Conditions
Polycystic Ovary Syndrome, Hypertension
Interventions
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
Interventions
PF-08052666
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2 Interventional Results available

MLE4901 vs. Placebo for the Treatment of PCOS

NCT02865915
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
MLE4901, Placebo
Drug
Lead sponsor
Millendo Therapeutics US, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Oceanside, California + 27 more
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer
Interventions
FAST Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
Interventions
Paclitaxel,Cisplatin, Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Normal Puberty
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Polycystic Ovary Syndrome
Interventions
Etonogestrel/ethinyl estradiol vaginal ring
Drug
Lead sponsor
Andrea Roe, MD, MPH
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Ovary Cancer
Interventions
EC1456, 99mTc-Etarfolatide
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Concord, North Carolina
Conditions
Progressive Metastatic Malignancies
Interventions
ALT-801
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Protein and Polycystic Ovary Syndrome (PCOS)

NCT07158723
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Higher protein dietary pattern, Calorie restriction
Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fayetteville, Arkansas
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Polycystic Ovary Syndrome, PCOS
Interventions
Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Polycystic Ovary Syndrome
Interventions
Oral Cinnamon Extract, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
23 Years to 47 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New York, New York
Suspended No phase listed Observational Accepts healthy volunteers

Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia

NCT02611128
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Puberty
Interventions
Phenotype/genotype assessment
Other
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 17 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ovarian Cancer
Interventions
Topotecan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Ovarian Neoplasms
Interventions
TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
234
States / cities
Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more